|
|
VGX
Pharmaceuticals Announces Formation of Animal Health Company
|
| Blue
Bell, PA – May 31, 2007 – |
|
VGX Pharmaceuticals Inc. (“VGX”)
announced today that it has formed a wholly owned subsidiary, VGX Animal
Health, Inc. (“VGX AH”). The newly established company will
include the animal health intellectual property and technology that came
to VGX as a result of its acquisition of ADViSYS in February of this year.
Additionally, VGX AH will have access to VGX’s adaptive electroporation
device, Cellectra™ for all animal health applications.
The VGX AH pipeline includes proprietary Growth Hormone Releasing Hormone
(“GHRH”) plasmid technology for major food and companion animals.
The company’s lead product, Life Tide SW5™ a GHRH porcine
product, is currently in registration in Australia. Also in Phase II of
development are canine GHRH products for renal failure and cancer related
cachexia and anemia. VGX AH has multiple product candidates in Phase I,
including indications for equine laminitis and arthritis.
VGX AH will be seeking alliance partners to help in its development and
commercialization efforts in major markets throughout the world.
Dr. J. Joseph Kim, President and CEO of VGX Pharmaceuticals, commented,
“The formation of VGX AH will allow us to maximize the commercial
potential of this important portfolio of animal health technologies, while
at the same time allowing us to maintain focus on the continued development
and expansion of our core human health biopharmaceutical business opportunities.”
Cautionary Factors That May Affect Future
Results - Materials in this Web site contain information
that includes or is based upon forward-looking statements within the
meaning of the Securities Litigation Reform Act of 1995. Forward-looking
statements relate to expectations or forecasts of future events. You
can identify these statements by the fact that they do not relate
strictly to historical or current facts. They use words such as "anticipate,"
"estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of
similar meaning in connection with a discussion of potential future
events, circumstances or future operating or financial performance.
In particular, these include statements relating to future actions,
prospective products or product approvals, future performance or results
of current and anticipated products, sales efforts, expenses, the
outcome of contingencies such as legal proceedings, and financial
results. Any or all of our forward-looking statements here or in other
publications may turn out to be wrong. They can be affected by inaccurate
assumptions or by known or unknown risks and uncertainties. Many such
factors will be important in determining our actual future results.
Consequently, no forward-looking statement can be guaranteed, and
forward-looking statements may be adversely affected by factors, including
general market conditions, competitive product development, product
availability, current and future branded and generic competition,
federal and state regulations and legislation, manufacturing issues,
timing of the elimination of trade buying, patent positions, litigations
and investigations. Our actual results may vary materially, and there
are no guarantees about the performance or valuation of VGX stock.
It is also important to read the disclosure notice contained in many
of the individual VGX documents available on this Web site as many
contain important information on such cautionary factors as of the
date of the individual document. We undertake no obligation to correct
or update any forward-looking statements, whether as a result of new
information, future events or otherwise. You are advised, however,
to consult any further disclosures we make on related subjects in
our reports. |
About VGX Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecules
and biologics product candidates for the treatment of infectious diseases,
cancer and inflammatory diseases. The Company’s clinical development
programs include PICTOVIR™ for HIV infection and VGX-410C for chronic
HCV infection, both of which are currently in Phase II clinical trials.
In addition, Phase I clinical trials will be initiated in 2007 for VGX-150
for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX’s
research pipelines include new generation of DNA vaccines and therapeutics
as well as CELLECTRA™, a proprietary DNA delivery device. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
